ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 184 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $34 | 0.0% | 1,586 | 0.0% | 0.00% | – |
Q2 2023 | $34 | -46.9% | 1,586 | 0.0% | 0.00% | – |
Q1 2023 | $64 | -22.0% | 1,586 | 0.0% | 0.00% | – |
Q4 2022 | $82 | -99.9% | 1,586 | 0.0% | 0.00% | – |
Q3 2022 | $82,000 | +9.3% | 1,586 | 0.0% | 0.00% | – |
Q2 2022 | $75,000 | -33.6% | 1,586 | 0.0% | 0.00% | – |
Q1 2022 | $113,000 | -85.4% | 1,586 | -87.7% | 0.00% | -100.0% |
Q3 2019 | $772,000 | -58.3% | 12,843 | -41.5% | 0.01% | -57.1% |
Q2 2019 | $1,852,000 | -16.8% | 21,947 | -5.8% | 0.01% | -22.2% |
Q1 2019 | $2,225,000 | -24.2% | 23,297 | -43.8% | 0.02% | -45.5% |
Q4 2018 | $2,934,000 | +61.7% | 41,421 | +95.2% | 0.03% | +135.7% |
Q3 2018 | $1,814,000 | – | 21,223 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |